<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39344920</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1522-9645</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>European heart journal</Title><ISOAbbreviation>Eur Heart J</ISOAbbreviation></Journal><ArticleTitle>Cardiovascular events following coronavirus disease 2019 vaccination in adults: a nationwide Swedish study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">ehae639</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/eurheartj/ehae639</ELocationID><Abstract><AbstractText Label="BACKGROUND AND AIMS" NlmCategory="OBJECTIVE">While the rationale for coronavirus disease 2019 (COVID-19) vaccination is to reduce complications and overall mortality, some cardiovascular complications from the vaccine itself have been demonstrated. Myocarditis and pericarditis are recognized as rare acute adverse events after mRNA vaccines in young males, while evidence regarding other cardiovascular events remains limited and inconsistent. This study assessed the risks of several cardiovascular and cerebrovascular events in a Swedish nationwide register-based cohort.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Post-vaccination risk of myocarditis/pericarditis, dysrhythmias, heart failure, myocardial infarction, and cerebrovascular events (transient ischaemic attack and stroke) in several risk windows after each vaccine dose were assessed among all Swedish adults (n = 8 070 674). Hazard ratios (HRs) with 95% confidence intervals (95% CIs) compared with unvaccinated were estimated from Cox regression models adjusted for potential confounders.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">For most studied outcomes, decreased risks of cardiovascular events post-vaccination were observed, especially after dose three (HRs for dose three ranging from .69 to .81), while replicating the increased risk of myocarditis and pericarditis 1-2 weeks after COVID-19 mRNA vaccination. Slightly increased risks, similar across vaccines, were observed for extrasystoles [HR 1.17 (95% CI 1.06-1.28) for dose one and HR 1.22 (95% CI 1.10-1.36) for dose two, stronger in elderly and males] but not for arrhythmias and for transient ischaemic attack [HR 1.13 (95% CI 1.05-1.23), mainly in elderly] but not for stroke.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Risk of myopericarditis (mRNA vaccines only), extrasystoles, and transient ischaemic attack was transiently increased after COVID-19 vaccination, but full vaccination substantially reduced the risk of several more severe COVID-19-associated cardiovascular outcomes, underscoring the protective benefits of complete vaccination.</AbstractText><CopyrightInformation>© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Yiyi</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-9106-0049</Identifier><AffiliationInfo><Affiliation>School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, BOX 414, 40 530 Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Huiqi</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-1127-0829</Identifier><AffiliationInfo><Affiliation>School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, BOX 414, 40 530 Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santosa</LastName><ForeName>Ailiana</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1848-2867</Identifier><AffiliationInfo><Affiliation>School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, BOX 414, 40 530 Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wettermark</LastName><ForeName>Björn</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-0531-2516</Identifier><AffiliationInfo><Affiliation>Pharmacoepidemiology and Social Pharmacy, Department of Pharmacy, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmacy Centre, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fall</LastName><ForeName>Tove</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-2071-5866</Identifier><AffiliationInfo><Affiliation>Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Björk</LastName><ForeName>Jonas</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-1883-2000</Identifier><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Division of Occupational and Environmental Medicine, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Studies Sweden, Forum South, Skåne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Börjesson</LastName><ForeName>Mats</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8786-0438</Identifier><AffiliationInfo><Affiliation>Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Lifestyle Intervention, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gisslén</LastName><ForeName>Magnus</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2357-1020</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Public Health Agency of Sweden, Solna, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nyberg</LastName><ForeName>Fredrik</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-0892-5668</Identifier><AffiliationInfo><Affiliation>School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, BOX 414, 40 530 Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>SciLifeLab National COVID-19 Research Program</Agency><Country /></Grant><Grant><GrantID>KAW 2021-0010/VC2021.0018</GrantID><Agency>Knut and Alice Wallenberg Foundation</Agency><Country /></Grant><Grant><GrantID>2021-05045</GrantID><Agency>Swedish Research Council</Agency><Country /></Grant><Grant><GrantID>20210030</GrantID><Agency>Swedish Heart-Lung Foundation</Agency><Country /></Grant><Grant><GrantID>ALFGBG-938453</GrantID><Agency>ALF agreement</Agency><Country /></Grant><Grant><Agency>Forte</Agency><Country /></Grant><Grant><GrantID>2020-02828</GrantID><Agency>FORMAS</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Heart J</MedlineTA><NlmUniqueID>8006263</NlmUniqueID><ISSNLinking>0195-668X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 vaccine</Keyword><Keyword MajorTopicYN="N">Cardiovascular diseases</Keyword><Keyword MajorTopicYN="N">Survival analysis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>16</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>16</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>7</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39344920</ArticleId><ArticleId IdType="doi">10.1093/eurheartj/ehae639</ArticleId><ArticleId IdType="pii">7795309</ArticleId></ArticleIdList></PubmedData></PubmedArticle>